Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells

Li,Meng; Peng,Zhongmin; Liu,Qingwei; Sun,Jian; Yao,Shuzhan; Liu,Qi

doi:10.3892/or.2012.2099

Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells

Authors:
- Meng Li
- Zhongmin Peng
- Qingwei Liu
- Jian Sun
- Shuzhan Yao
- Qi Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong 250021, P.R. China, PET/CT Center, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong 250021, P.R. China, Cancer Center, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: October 23, 2012 https://doi.org/10.3892/or.2012.2099
Pages: 205-211

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the efficacy of 11C-choline PET/CT imaging for lung cancer and the correlation between choline uptake of lung cancer tissue and the expression of choline kinase (ChoK), phosphorylcholine-cytidyl transferase and Ki-67 index. Between March 2008 and June 2010, 53 patients diagnosed or suspected of having lung cancer underwent integrated 11C-choline PET/CT and contrast-enhanced CT scans before surgery. After surgery, specimens from 42 patients diagnosed with lung cancer were used to detect the expression of ChoK, phosphorylcholine-cytidyl transferase and the Ki-67 index. The PET/CT results were analyzed using visual methods and the standardized uptake value (SUV) of lesions was measured using semi-quantitative methods. Finally, the analyzed results were compared to the histopathological results. The accuracy of the 11C-choline PET/CT for diagnosing lung cancer was 81.13% (43/53), compared with 71.70% (38/53) for CT scanning. The difference was not statistically significant (P=0.61). The accuracy of 11C-choline PET/CT for diagnosing lymph nodes was 83.76% (227/271), compared with 66.79% (181/271) for CT scanning. This difference was statistically significant (P=0.04); the SUVmean value of lesions correlated positively with the Ki-67 index (r=0.51, p=0.002). Of the 35 patients with positive 11C-choline PET results, 29 (82.86%) overexpressed ChoK, 26 (74.29%) overexpressed phosphorylcholine-cytidyl transferase. The seven patients with negative 11C-choline PET results did not exhibit overexpression of ChoK or phosphorylcholine-cytidyl transferase; the SUVmean value correlated positively with the expression of both ChoK and phosphorylcholine-cytidyl transferase (r=0.52, p=0.001; r=0.37, p=0.029). In conclusion, compared with contrast-enhanced CT, 11C-choline PET offers nodal staging with higher accuracy. The SUV value of PET is correlated with the proliferation of tumor cells and the mechanism of PET imaging is associated with the overexpression of ChoK and phosphorylcholine-cytidyl transferase.

View Figures

View References

1	Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA, et al: Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest. 125:2300–2308. 2004. View Article : Google Scholar
2	Silvestri GA, Tanoue LT, Margolis ML, Barker J and Detterbeck F: The noninvasive staging of non-small cell lung cancer: the guidelines. Chest. 123:S147–S156. 2003. View Article : Google Scholar : PubMed/NCBI
3	Spaggiari L, Sverzellati N, Versari A, Paci M, Ferrari G, Nicoli F, et al: Evaluation of N parameter in the staging of non-small cell lung cancer: role of CT and PET. Radiol Med. 109:449–459. 2005.PubMed/NCBI
4	Aeker MR and Burrell SC: Utility of ¹⁸F-FDG PET in evaluating cancers of lung. J Nucl Med Technol. 33:69–74. 2005.
5	Shiraki N, Hara M, Ogino H, Shibamoto Y, Iida A, Tamaki T, Murase T and Eimoto T: False-positive and true-negative hilar and mediastinal lymph nodes on FDG-PET - radiological-pathological correlation. Ann Nucl Med. 18:23–28. 2004. View Article : Google Scholar : PubMed/NCBI
6	Hara T, Kosaka N, Suzuki T, Kudo K and Niino H: Uptake rates of ¹⁸F-fluorodeoxyglucose and ¹¹C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest. 124:893–901. 2003.
7	Tian M, Zhang H, Oriuchi N, et al: Comparison of ¹¹C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging. 31:1064–1072. 2004.
8	Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, Morikawa T, Kinoshita I, Dosaka-Akita H and Nishimura M: Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration. 70:500–506. 2003. View Article : Google Scholar : PubMed/NCBI
9	Hara T, Inagaki K, Kosaka N and Morita T: Sensitive detection of mediastinal lymph node metastasis of lung cancer with ¹¹C-choline PET. J Nucl Med. 41:1507–1513. 2000.PubMed/NCBI
10	Roivainen A, Forsback S, Gronroos T, et al: Blood metabolism of [methyl-¹¹C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 27:25–32. 2000.
11	Golfman LS, Bakovic M and Vance E: Transcription of the CTP: phosphocholine cytidylyltransferase alpha gene is enhanced during the S phase of the cell cycle. J Biol Chem. 276:43688–43692. 2001. View Article : Google Scholar : PubMed/NCBI
12	Janardhan S, Srivani P and Sastry GN: Choline kinase: an important target for cancer. Curr Med Chem. 13:1169–1186. 2006. View Article : Google Scholar : PubMed/NCBI
13	Agassandian M, Zhou J, Tephly LA, et al: Oxysterols inhibit phosphatidylcholine synthesis via ERKdocking and phosphorylation of CTP:phosphocholine cytidylyltransferase. J Biol Chem. 280:21577–21587. 2005. View Article : Google Scholar
14	Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 91:2018–2025. 2004. View Article : Google Scholar : PubMed/NCBI
15	Nakamura H, Hirata T, Kitamura H and Nishikawa J: Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg. 15:304–310. 2009.PubMed/NCBI
16	Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y and Ohkawa M: Correlation of ¹⁸F-FLT and ¹⁸F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 34:1610–1616. 2007.
17	Takenaka T, Yano T, Ito K, Morodomi Y, Miura N, Kawano D, Shoji F, Abe K, Honda H and Maehara Y: Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer. J Surg Oncol. 100:688–692. 2009. View Article : Google Scholar : PubMed/NCBI
18	Han B, Lin S, Yu LJ, Wang RZ and Wang YY: Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 30:214–219. 2009.
19	Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC and Kim SE: FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol. 62:214–219. 2007. View Article : Google Scholar : PubMed/NCBI
20	Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, Vallières E and Wood DE: Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 3:971–978. 2008. View Article : Google Scholar : PubMed/NCBI